FPS-Holding
VC Fund
FPS-Holding is a VC fund focused on Biotechnology and Health Diagnostics. SPV
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries FPS-Holding invests in
Stages FPS-Holding invests in
Countries FPS-Holding invests in
Round sizes
Round size
- Seed
- $420k–$1.5M
Investment Focus
Industry
- Biotechnology 1 (33%)
- Health Diagnostics 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sola Diagnostics
|
Product: Sola Diagnostics’ WID®-easy test is a non-invasive epigenetic solution for detecting endometrial cancer in women with abnormal uterine bleeding. By analyzing DNA methylation markers from a simple vaginal swab, it offers high accuracy, reducing false positives and unnecessary surgeries. Target Audience: Designed for gynecologists andhealthcare providers, WID®-easy streamlines diagnostics, cutting costs and false alarms. Women benefit from a painless, accessible test that ensures earlier and more precise detection. Technology: Powered by advanced DNA methylation research, WID®-easy identifies cancer-specific epigenetic markers. With PCR-based analysis and robust clinical validation, it delivers fast, reliable results that integrate seamlessly into medical workflows. Market Positioning: WID®-easy fills a critical gap as a first-line diagnostic for abnormal uterine bleeding. Its clinical validation, accuracy, and cost-efficiency set it apart from invasive procedures. Its ease of use and scalability position it for widespread adoption. Milestones: Sola Diagnostics launched in Austria and Switzerland in 2024 and expanded to Great Britain in 2025. UKCA Marking was registered in December 2024. So far, private equity investments totaling €2.4M have supported Sola's mission to revolutionize women’s health diagnostics. | $420.1K / Seed / Feb 20, 2025 | |
|
Sola Diagnostics
|
Product: Sola Diagnostics’ WID®-easy test is a non-invasive epigenetic solution for detecting endometrial cancer in women with abnormal uterine bleeding. By analyzing DNA methylation markers from a simple vaginal swab, it offers high accuracy, reducing false positives and unnecessary surgeries. Target Audience: Designed for gynecologists andhealthcare providers, WID®-easy streamlines diagnostics, cutting costs and false alarms. Women benefit from a painless, accessible test that ensures earlier and more precise detection. Technology: Powered by advanced DNA methylation research, WID®-easy identifies cancer-specific epigenetic markers. With PCR-based analysis and robust clinical validation, it delivers fast, reliable results that integrate seamlessly into medical workflows. Market Positioning: WID®-easy fills a critical gap as a first-line diagnostic for abnormal uterine bleeding. Its clinical validation, accuracy, and cost-efficiency set it apart from invasive procedures. Its ease of use and scalability position it for widespread adoption. Milestones: Sola Diagnostics launched in Austria and Switzerland in 2024 and expanded to Great Britain in 2025. UKCA Marking was registered in December 2024. So far, private equity investments totaling €2.4M have supported Sola's mission to revolutionize women’s health diagnostics. | $429.3K / Seed / Jun 24, 2024 | |
|
Sola Diagnostics
|
Product: Sola Diagnostics’ WID®-easy test is a non-invasive epigenetic solution for detecting endometrial cancer in women with abnormal uterine bleeding. By analyzing DNA methylation markers from a simple vaginal swab, it offers high accuracy, reducing false positives and unnecessary surgeries. Target Audience: Designed for gynecologists andhealthcare providers, WID®-easy streamlines diagnostics, cutting costs and false alarms. Women benefit from a painless, accessible test that ensures earlier and more precise detection. Technology: Powered by advanced DNA methylation research, WID®-easy identifies cancer-specific epigenetic markers. With PCR-based analysis and robust clinical validation, it delivers fast, reliable results that integrate seamlessly into medical workflows. Market Positioning: WID®-easy fills a critical gap as a first-line diagnostic for abnormal uterine bleeding. Its clinical validation, accuracy, and cost-efficiency set it apart from invasive procedures. Its ease of use and scalability position it for widespread adoption. Milestones: Sola Diagnostics launched in Austria and Switzerland in 2024 and expanded to Great Britain in 2025. UKCA Marking was registered in December 2024. So far, private equity investments totaling €2.4M have supported Sola's mission to revolutionize women’s health diagnostics. | $1.5M / Seed / Mar 11, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does FPS-Holding invest in?
FPS-Holding invests primarily in Biotechnology and Health Diagnostics startups, most often at Seed stage. Most of the 3 investments tracked by Shizune back companies in Austria. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is FPS-Holding's check size?
FPS-Holding typically joins rounds of $420k–$1.5M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds FPS-Holding participates in.
When did FPS-Holding last invest?
The most recent investment recorded for FPS-Holding closed in Feb 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
